Editas Medicine, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
EDIT Company Description
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
EDIT Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view EDIT Smart Score
Score Breakdown
EDIT Company Description
Show More
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of EDIT by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by EDIT's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on EDIT's company Twitter account
WallStreetBets
Number of mentions of EDIT in WallStreetBets Daily Discussion
EDIT News
Recent insights relating to EDIT
CNBC Recommendations
Recent picks made for EDIT stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in EDIT
Corporate Flights
Flights by private jets registered to EDIT
Our Analysis